Nyrada, Inc.ASX: NYR

PROTECT-MI Phase IIa Clinical Trial Update No 4

· Issued by Nyrada, Inc. via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Nyrada, Inc. provides an update on its PROTECT-MI Phase IIa clinical trial, highlighting the activation of five trial sites and the dosing of five patients as of the latest report. Nyrada is also preparing for a US IND submission for its drug Xolatryp, targeting early next year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/protect-mi-phase-iia-clinical-trial-update-no-4

Release

30 October 2026 Sydney, Australia PROTECT-MI Phase IIa Clinical Trial Update #4 Highlights: • Five (5) sites now activated, and five (5) patients now dosed, up from three at last update on 16 October 2026. • Recruitment progressing towards the eighth patient, which triggers the first Safety...

Nyrada, Inc. on 6ix

Earlier from Nyrada

Later from Nyrada

All Nyrada news releases